Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Insulin for Glaucoma and Optic Neuropathies
NCT05206877Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human insulin in Glaucoma, ischemic optic neuropathy (ION) and optic disc drusen (ODD) (7 arms), sponsored by Stanford University. Primary endpoint: Number of Participants with Treatment-Related Adverse Events at 2 months. Started Apr 2022; status: recruiting.
02
Drugs
human insulin
03
Conditions
Glaucomaischemic optic neuropathy (ION)optic disc drusen (ODD)
Beyond the preview
Go deeper on NCT05206877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206877.